Cargando…

The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock

The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishimaru, Kayoko, Nakajima, Shotaro, Yu, Guannan, Nakamura, Yuki, Nakao, Atsuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941044/
https://www.ncbi.nlm.nih.gov/pubmed/31847374
http://dx.doi.org/10.3390/ijms20246320
_version_ 1783484471473864704
author Ishimaru, Kayoko
Nakajima, Shotaro
Yu, Guannan
Nakamura, Yuki
Nakao, Atsuhito
author_facet Ishimaru, Kayoko
Nakajima, Shotaro
Yu, Guannan
Nakamura, Yuki
Nakao, Atsuhito
author_sort Ishimaru, Kayoko
collection PubMed
description The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and metabolic disorders. The nuclear receptors REV-ERB-α and -β (REV-ERBs) are crucial components of the circadian clockwork. Efforts to pharmacologically target REV-ERBs using putatively specific synthetic agonists, particularly SR9009, have yielded beneficial effects on sleep and metabolism. Here, we sought to determine whether REV-ERBs are functional in the circadian clockwork in mast cells and, if so, whether SR9009 affects IgE- and IL-33-mediated mast cell activation. Bone marrow-derived mast cells (BMMCs) obtained from wild-type mice expressed REV-ERBs, and SR9009 or other synthetic REV-ERBs agonists affected the mast cell clockwork. SR9009 inhibited IgE- and IL-33-mediated mast cell activation in wild-type BMMCs in association with inhibition of Gab2/PI3K and NF-κB activation. Unexpectedly, these suppressive effects of SR9009 were observed in BMMCs following mutation of the core circadian gene Clock. These findings suggest that SR9009 inhibits IgE- and IL-33-mediated mast cell activation independently of the functional circadian clock activity. Thus, SR9009 or other synthetic REV-ERB agonists may have potential for anti-allergic agents.
format Online
Article
Text
id pubmed-6941044
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69410442020-01-09 The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock Ishimaru, Kayoko Nakajima, Shotaro Yu, Guannan Nakamura, Yuki Nakao, Atsuhito Int J Mol Sci Article The cell-autonomous circadian clock regulates IgE- and IL-33-mediated mast cell activation, both of which are key events in the development of allergic diseases. Accordingly, clock modifiers could be used to treat allergic diseases, as well as many other circadian-related diseases, such as sleep and metabolic disorders. The nuclear receptors REV-ERB-α and -β (REV-ERBs) are crucial components of the circadian clockwork. Efforts to pharmacologically target REV-ERBs using putatively specific synthetic agonists, particularly SR9009, have yielded beneficial effects on sleep and metabolism. Here, we sought to determine whether REV-ERBs are functional in the circadian clockwork in mast cells and, if so, whether SR9009 affects IgE- and IL-33-mediated mast cell activation. Bone marrow-derived mast cells (BMMCs) obtained from wild-type mice expressed REV-ERBs, and SR9009 or other synthetic REV-ERBs agonists affected the mast cell clockwork. SR9009 inhibited IgE- and IL-33-mediated mast cell activation in wild-type BMMCs in association with inhibition of Gab2/PI3K and NF-κB activation. Unexpectedly, these suppressive effects of SR9009 were observed in BMMCs following mutation of the core circadian gene Clock. These findings suggest that SR9009 inhibits IgE- and IL-33-mediated mast cell activation independently of the functional circadian clock activity. Thus, SR9009 or other synthetic REV-ERB agonists may have potential for anti-allergic agents. MDPI 2019-12-14 /pmc/articles/PMC6941044/ /pubmed/31847374 http://dx.doi.org/10.3390/ijms20246320 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ishimaru, Kayoko
Nakajima, Shotaro
Yu, Guannan
Nakamura, Yuki
Nakao, Atsuhito
The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title_full The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title_fullStr The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title_full_unstemmed The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title_short The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock
title_sort putatively specific synthetic rev-erb agonist sr9009 inhibits ige- and il-33-mediated mast cell activation independently of the circadian clock
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941044/
https://www.ncbi.nlm.nih.gov/pubmed/31847374
http://dx.doi.org/10.3390/ijms20246320
work_keys_str_mv AT ishimarukayoko theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakajimashotaro theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT yuguannan theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakamurayuki theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakaoatsuhito theputativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT ishimarukayoko putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakajimashotaro putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT yuguannan putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakamurayuki putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock
AT nakaoatsuhito putativelyspecificsyntheticreverbagonistsr9009inhibitsigeandil33mediatedmastcellactivationindependentlyofthecircadianclock